New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...

Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the ...

A new research perspective was published in Oncotarget's Volume 15 on September 4, 2024, entitled, "Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and potential therapeutic targets. The team used their reference map for normal ...

A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's unique ...